News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Launches Vesicare for the Treatment of Overactive Bladder in the US

January 20, 2005

Tokyo, Japan - January 20, 2005 - Yamanouchi Pharmaceutical Co., Ltd. (president: Toichi Takenaka) announced that Vesicare (generic name: solifenacin succinate) is now available in the US market. The US Food and Drug Administration (FDA) approved Vesicare in November 2004 for the treatment of overactive bladder with symptoms of urgency, frequency and urge incontinence in the United States. It is marketed and copromoted by Yamanouchi Pharma America Inc. (YPA), a Yamanouchi's US subsidiary and GlaxoSmithKline (GSK) in the US.

When orally administered once a day, Vesicare relaxes the detrusor muscle by blocking the muscarinic (nerve) receptors in it, thereby reducing overactive bladder symptoms of urgency, frequency and urge incontinence. In fact, multiple clinical trials showed that Vesicare significantly reduced urinary incontinence episodes over the 12 week study period. While overactive bladder affects an estimated 17 to 20 million men and women in the United States, the number of patients who receive treatment is limited because many mistakenly believe this is a natural part of aging or are embarrassed to discuss it with physicians. Patients gradually develop coping behaviors to manage their symptoms such as restricting fluids, "mapping" bathroom locations, or even choosing not to leave the house.

At present, Yamanouchi is constructing a marketing system of its own in the US focusing on the urology field. It is now promoting the treatment of functional symptoms of benign prostatic hyperplasia Flomax (brand name in Japan: Harnal), but Vesicare is the first product the company independently markets in the United States. YPA promotes Vesicare targeting specialists such as urologists and gynecologists based on the copromotion agreement YPA concluded with GSK in August 2003. In the primary care market, promotion will be conducted mainly by GSK and partly by YPA. Yamanouchi plans to quickly and efficiently penetrate the market through promotion by YPA and GSK.

Urology will be one of the focus fields for Astellas Pharma Inc. which will be formed as a result of merger of Yamanouchi and Fujisawa Pharmaceutical Co., Ltd. in April. As an important strategic product, Vesicare is expected to make significant contribution to further expansion and consolidation of the company's business platform in the US.